Medtronic (MDT) Suffers a Larger Drop Than the General Market: Key Insights

Medtronic (MDT) closed at $94.30 in the latest trading session, marking a -1.5% move from the prior day. This change lagged the S&P 500's daily loss of 0.5%. Elsewhere, the Dow lost 0.38%, while the tech-heavy Nasdaq lost 0.5%. Prior to today's trading, shares of the medical device company had gained 4.01% outpaced the Medical sector's loss of 0.7% and the S&P 500's gain of 2.74%.Analysts and investors alike will be keeping a close eye on the performance of Medtronic in its upcoming earnings disclosure. The company's earnings report is set to go public on November 18, 2025. The company's earnings per share (EPS) are projected to be $1.31, reflecting a 3.97% increase from the same quarter last year. Our most recent consensus estimate is calling for quarterly revenue of $8.84 billion, up 5.26% from the year-ago period. For the full year, the Zacks Consensus Estimates project earnings of $5.62 per share and a revenue of $35.83 billion, demonstrating changes of +2.37% and +6.82%, respectively, from the preceding year. It's also important for investors to be aware of any recent modifications to analyst estimates for Medtronic. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook. Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system. The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. Medtronic is currently sporting a Zacks Rank of #3 (Hold). Looking at its valuation, Medtronic is holding a Forward P/E ratio of 17.05. This signifies a discount in comparison to the average Forward P/E of 18.3 for its industry. We can also see that MDT currently has a PEG ratio of 2.52. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The average PEG ratio for the Medical - Products industry stood at 2.28 at the close of the market yesterday. The Medical - Products industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 95, placing it within the top 39% of over 250 industries. The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions. Research Chief Names "Single Best Pick to Double"From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Medtronic PLC (MDT): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks